SCI Engineered Materials, Inc.: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 2, 2020 and accepted by EDGAR at Nov 2, 2020, 08:15 ET.
Management's discussion and analysis
As filed, 3,880 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
RESULTS OF OPERATIONS
Three and nine months ended September 30, 2020 (unaudited) compared to three and nine months ended September 30, 2019 (unaudited):
Revenue
For the three months ended September 30, 2020, we had total revenue of $1,494,078. This was a decrease of $1,761,123 or 54.1%, compared to the three months ended September 30, 2019. For the nine months ended September 30, 2020, we had total revenue of $7,539,460. This was a decrease of $2,472,727 or 24.7%, compared to the nine months ended September 30, 2019. Total revenue was adversely impacted by lower volume, pricing and COVID-19 related issues compared to the same periods in 2019.
Gross Profit
Gross profit was $459,139 for the three months ended September 30, 2020 compared to $458,520 for the same three months in 2019. Gross profit was $1,406,261 for the nine months ended September 30, 2020 compared to $1,849,491 for the first nine months of 2019. This was a decrease of $443,230 or 24.0%. The decrease in gross profit for the first nine months of 2020 was primarily related to the lower revenue previously mentioned. Gross profit as a percentage of revenue (gross margin) was 30.7% for the third quarter of 2020 compared to 14.1% for the same period in 2019. The improved third quarter 2020 gross margin was due to pricing, product mix and improved manufacturing efficiency. The third quarter of 2019 included more revenue generated from a high priced, low margin raw material that contributed to the lower gross margin in that period. Gross margin was 18.7% for the first nine months of 2020 compared to 18.5% for the same period in 2019. As we continue to implement our growth strategy in complementary niche markets, it is anticipated the Company’s gross margin will improve from the 2020 year-to-date percentage although it will continue to be influenced by product mix and price fluctuation of a high priced, low margin raw material for the foreseeable future.
General and Administrative Expense
General and administrative expense for the three months ended September 30, 2020 and 2019, was $263,444 and $247,984, respectively, an increase of 6.2%. This increase was related to higher compensation and business insurance expenses in 2020. General and administrative expense for the nine months ended September 30, 2020 and 2019, was $818,825 and $957,420, respectively, a decrease of 14.5%. This decrease was primarily due to lower compensation of approximately $127,000 in 2020 versus 2019 related to expense incurred during our management transition in the first half of 2019.
Professional Fees
Included in total expense was $39,694 and $39,799 for professional fees for the three months ended September 30, 2020 and 2019, respectively and $159,831 and $160,252 for the nine months ended September 30, 2020 and 2019, respectively. These expenses were primarily related to SEC compliance costs for legal, accounting and stockholder relations fees.
Research and Development Expense
Research and development expense for the three months ended September 30, 2020, was $83,276 compared to $80,203 for the same period in 2019, an increase of 3.8%. Research and development expense for the nine months ended September 30, 2020, was $260,601 compared to $283,672 for the same period in 2019, a decrease of 8.1%. This decrease was primarily related to lower compensation expense due to staffing levels in 2019. We continue to invest in developing new applications for our markets including electrically conductive Zinc Tin Oxide for Thin Film Solar, Architectural Glass and Thin-Film Transistors. Specialty materials are being researched for use in niche markets such as additive manufacturing. Our development efforts utilize a disciplined innovation approach focused on accelerating time to market for these applications and involve ongoing research and development expense.
Controls and procedures
As filed, 3,906 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Management previously disclosed a material weakness in internal control over financial reporting in its annual report on Form 10-K, filed on February 5, 2020, for the year ended December 31, 2019, relating to insufficient segregation of duties consistent with control objectives. Management is aware of the risks associated with the lack of segregation of duties due to the small number of employees currently working with general administrative and financial matters. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions shall be performed by separate individuals.
To address and remediate the material weakness in internal control over financial reporting described above, we performed a review of our related procedures and controls and strengthened cross approval of various functions, including financial reporting and disclosure review controls by the Chief Financial Officer, to include the Chief Executive Officer and Audit Committee Chairperson where appropriate. We continue to report to the Audit Committee and the Board of Directors at least monthly (and more often as necessary). This reporting includes balance sheets, statements of operations, statements of cash flows, and other detail supporting these statements.
Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective. Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act as controls and other procedures that are designed to ensure that information required to be disclosed by us in reports filed with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
Inherent Limitations over Internal Controls
Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of assets that could have a material effect on the financial statements.
Management is responsible for the consistency, integrity, and presentation of information. We fulfill our responsibility by maintaining systems of internal control designed to provide reasonable assurance that assets are safeguarded and transactions are executed in accordance with established procedures. The concept of reasonable assurance is based upon recognition that the cost of the controls should not exceed the benefit derived. We believe our systems of internal control provide this reasonable assurance.
The Board of Directors exercises its oversight role with respect to our systems of internal control primarily through its Audit Committee, which is comprised of independent directors. The Committee oversees our financial reporting, quarterly reviews and audits to assess whether their quality, integrity, and objectivity are sufficient to protect shareholders’ investments.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $1.5m | us-gaap:Revenues |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $7.5m | us-gaap:Revenues |
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $1.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $6.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2020-07-01 to 2020-09-30 | $459.1k | us-gaap:GrossProfit |
| Gross profit | 9 months2020-01-01 to 2020-09-30 | $1.4m | us-gaap:GrossProfit |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $83.3k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $260.6k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | $67.6k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | $182.8k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $1.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | $58.5k | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | $160.5k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | $0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | $0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | $0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 4,447,059 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 4,420,272 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | $504.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $49.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-09-30 | $2.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $4.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $6.6m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $1.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $2.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-09-30 | $4.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-20-120266. Last ingested by Listed: Oct 29, 2026, 08:02 ET. Listed shows no prices and gives no investment advice.